The location of the peroneus longus tendon in the cuboid groove: sonographic study in various positions of the ankle–foot in asymptomatic volunteers

Abstract

Objective

To evaluate the normal location of the peroneus longus tendon (PL) in the cuboid groove in various ankle–foot positions by ultrasonography in asymptomatic volunteers.

Materials and methods

Ultrasonographic assessment of the PL in the cuboid groove was performed in 20 feet of ten healthy volunteers. Each PL was examined in five ankle–foot positions (i.e., neutral, dorsiflexion, plantar-flexion, supination, and pronation). The PL location was qualitatively categorized as "inside" when the PL was entirely within the cuboid groove, as "overlying" when some part of the PL was perched on the cuboid tuberosity, and as "outside" when the PL was entirely on the cuboid tuberosity. For quantitative evaluation of the PL location, the distance between the PL and the cuboid groove was measured. The width of the cuboid groove was measured in the neutral position.

Results

The PL location did not significantly change with changes in the ankle–foot position. Qualitatively, an "overlying" PL was the most common type, regardless of the ankle–foot position. "Inside" PLs were found in only 35, 20, 30, 25, and 35% of feet in neutral, dorsiflexion, plantar-flexion, supination, and pronation positions, respectively. The quantitative PL location was also not significantly different among all ankle–foot positions and it was significantly negatively correlated with the cuboid groove width.

Conclusions

In healthy volunteers, 65% or more of the PLs were partially or completely located outside of the cuboid groove, regardless of the ankle–foot position. The PL location relative to the cuboid groove was related to the cuboid groove width.

from Imaging via alkiviadis.1961 on Inoreader https://ift.tt/2qfg19l

Stereotactic ablative radiotherapy after concomitant chemoradiotherapy in non-small cell lung cancer: A TITE-CRM phase 1 trial

Platinum based chemoradiotherapy is the standard of care for inoperable non-small cell lung cancer (NSCLC). With evidence that NSCLC can have a dose dependent response with stereotactic ablative radiotherapy (SABR), we hypothesize that a SABR boost on residual tumor treated with chemoradiotherapy could increase treatment efficacy. The purpose of this study was to determine feasibility of such an approach.

from Imaging via alkiviadis.1961 on Inoreader https://ift.tt/2Exm3Xj

Stereotactic ablative radiotherapy after concomitant chemoradiotherapy in non-small cell lung cancer: A TITE-CRM phase 1 trial

Publication date: Available online 9 April 2018
Source:Radiotherapy and Oncology
Author(s): Jérôme Doyen, Michel Poudenx, Jocelyn Gal, Josiane Otto, Caroline Guerder, Arash O. Naghavi, Anais Gérard, Axel Leysalle, Charlotte Cohen, Bernard Padovani, Antoine Ianessi, Renaud Schiappa, Emmanuel Chamorey, Pierre-Yves Bondiau
Background and purposePlatinum based chemoradiotherapy is the standard of care for inoperable non-small cell lung cancer (NSCLC). With evidence that NSCLC can have a dose dependent response with stereotactic ablative radiotherapy (SABR), we hypothesize that a SABR boost on residual tumor treated with chemoradiotherapy could increase treatment efficacy. The purpose of this study was to determine feasibility of such an approach.Material and methodsA prospective phase I trial was performed including 26 patients. Time-to-event continual reassessment method (TITE-CRM) was used for dose escalation which ranged from 3 × 7 to 3 × 12 Gy for the stereotactic boost, after 46 Gy (2 Gy per day) of chemoradiotherapy.ResultsMedian follow-up was of 37.1 months (1.7–60.7), and 3, 4, 3, 3, 9 and 4 patients were included at the dose levels 1, 2, 3, 4, 5 and 6, respectively. During chemoradiotherapy, 9 patients experienced grade 3 toxicity. After stereotactic radiotherapy, 1 patient experienced an esophageal fistula (with local relapse) at the 3 × 11 Gy level, and 1 patient died from hemoptysis at the 3 × 12 Gy level. The 2-year rate of local control, locoregional free survival, metastasis-free survival, and overall survival was 70.3%, 55.5%, 44.5% and 50.8%, respectively.ConclusionIn the treatment of NSCLC with chemoradiotherapy followed by a stereotactic boost, the safe recommended dose in our protocol was a boost dose of 3 × 11 Gy.



from Imaging via alkiviadis.1961 on Inoreader https://ift.tt/2HlXU8N

Perimesencephalic SAH: DAMS Unplugged

Perimesencephalic subarachnoid haemorrhage  implies subarachnoid haemorrhage (SAH) centred on the basal cisterns around the midbrain. Here is a brief teaching video explaining the same

Famous Radiology Blog https://ift.tt/1MM2hKr TeleRad Providers at https://ift.tt/1NgppuI Mail us at sales@teleradproviders.com

from Imaging via alkiviadis.1961 on Inoreader https://ift.tt/2Hli96G

Pacinian corpuscles: an explanation for subcutaneous palmar nodules routinely encountered on MR examinations

Abstract

Pacinian corpuscles, the main touch receptors to pressure and vibration, are ubiquitous in the deep dermis and hypodermis of the fingers and palms. Nevertheless, their existence is largely unknown to most radiologists. We frequently noted hyperintense nodules in the palms of patients on water-sensitive MRI sequences, but were unable to explain their etiology. We recently encountered two patients who had Pacinian corpuscles identified at surgical exploration and pathological analysis. Pre-operative MRI examinations in these patients showed T2 hyperintense subcutaneous palmar nodules corresponding to these corpuscles in a pattern identical to those seen incidentally in other patients. Descriptions from the dermatopathological and orthopedic literature closely correspond to our MRI observations. Based on these data, we hypothesize that the MRI finding that we previously noted represents normal Pacinian corpuscles.

from Imaging via alkiviadis.1961 on Inoreader https://ift.tt/2EvrhCP